News

Organogenesis, Inc., the world's leading regenerative medicine company, announced today that Apligraf®, its living bi-layered cell therapy product used to treat non-healing wounds, has gained Swiss reimbursement, beginning August 1.

"Swiss patients with non-healing wounds are the first in Europe to benefit from a fully reimbursed regenerative medicine therapy with Apligraf," said Geoff Mackay, CEO of Organogenesis. "As pioneers in the translation of regenerative medicine technology from visionary science to treatments used in everyday medical care, Organogenesis is proud to lead the way in introducing living cell therapies to patients around the world."

Organogenesis is the first company to successfully mass produce living regenerative medicine products -- reaching hundreds of thousands of patients in the U.S. and around the world. Its signature product, Apligraf, is the first living cell therapy to have received U.S. Food and Drug Administration (FDA) approvals to close diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).

Clinical studies have shown that Apligraf in combination with a standard therapy is more efficient in healing diabetic foot ulcers than standard therapy alone(i,ii). Over 200,000 patients around the world have been treated with Apligraf to date.

"Patients suffering from diabetes or from circulatory (venous) insufficiencies often have long-lasting open wounds. Those may last over several years, and they significantly lower the quality of life," said Dr. Fiorenzo Angehrn, surgeon and head of the clinic Piano in Biel, Switzerland, who has successfully treated patients with Apligraf for several years. "Many chronic wounds need to be treated with an active wound healing product, and therefore we welcome Apligraf as a true medical advancement."